Fresenius, Akorn Deal Hangs in Limbo

Overview


William Diaz and Jonathan Ende were authors of a blog post, cited here, in which they discussed a potential divestiture that the FTC may require for approval of German health care companyFresenius’ nearly $5 billion deal forU.S. generic drugmaker Akorn.